Study: Comparing biosimilar of ranibizumab and Lucentis in efficacy and safety for wet AMD

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

Enrollment completed in Phase 2 ENVISION clinical trial

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

European Commission approves faricimab for nAMD, DME

Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.

Ashvattha Therapeutics enrolls first patient in Phase 2 study of D-4517.2 for treatment of wet AMD, DME

September 07, 2022

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.